VEGFA and diabetes mellitus: MIAT down-regulation alleviates retinal vessel impairment, in vivo, by reducing vascular leakage and counteracting the DM-induced up-regulation of proinflammatory proteins such as ICAM-1, TNF-α, and VEGF.